Amneal Announces Complete Response Resubmission for IPX203 New Drug Application
February 08, 2024 16:05 ET
|
Amneal Pharmaceueticals, Inc.
BRIDGEWATER, N.J., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced that it has provided a Complete Response resubmission to...